Literature DB >> 1980537

Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain.

C R Chapman1, H F Hill, L Saeger, J Gavrin.   

Abstract

This report examines the relationship of plasma drug concentration to analgesic effect following bolus doses of alfentanil, fentanyl and morphine and assesses individual differences in analgesic response among volunteers. We predicted that the 3 opioids would yield disparate analgesic profiles because their physicochemical and pharmacokinetic characteristics differ. Ten healthy volunteers received intravenous bolus doses of either alfentanil, fentanyl, morphine or normal saline on different days. We stimulated their teeth electrically and measured brain evoked potential (EP) and pain report (PR) repeatedly over 2 h to assess analgesic effect. Concurrently, we drew 18 blood samples to assess opioid plasma concentrations during the test period. The relationship between opioid plasma concentration and analgesic effect was well defined for alfentanil but ambiguous for morphine. Fentanyl exhibited a marked hysteresis. We observed noteworthy individual differences in analgesic response with all 3 drugs but these differences were greatest for morphine and least for alfentanil. Inter- and intrasubject variability in analgesic response across drugs is related to the physicochemical properties of the drugs tested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980537     DOI: 10.1016/0304-3959(90)90049-J

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  10 in total

Review 1.  Pharmacokinetic optimisation of opioid treatment in acute pain therapy.

Authors:  R N Upton; T J Semple; P E Macintyre
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

2.  Summary of the scientific literature for pain and anxiety control in dentistry.

Authors:  L C Hassett
Journal:  Anesth Prog       Date:  1991 May-Jun

3.  Single-sweep spectral analysis of contact heat evoked potentials: a novel approach to identify altered cortical processing after morphine treatment.

Authors:  Tine M Hansen; Carina Graversen; Jens B Frøkjaer; Anne E Olesen; Massimiliano Valeriani; Asbjørn M Drewes
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 4.  The genetic mediation of individual differences in sensitivity to pain and its inhibition.

Authors:  J S Mogil
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex.

Authors:  B H Manning; N M Merin; I D Meng; D G Amaral
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

6.  The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

Authors:  Evan D Kharasch; Christine Hoffer; Dale Whittington
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 7.  Choosing the right analgesic. A guide to selection.

Authors:  Timothy G Bushnell; Douglas M Justins
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 8.  Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review.

Authors:  Camilla Staahl; Anne Estrup Olesen; Trine Andresen; Lars Arendt-Nielsen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 9.  Electroencephalography and analgesics.

Authors:  Lasse Paludan Malver; Anne Brokjaer; Camilla Staahl; Carina Graversen; Trine Andresen; Asbjørn Mohr Drewes
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

10.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.